Technical Analysis for XRTX - Xortx Therapeutics Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 4.070 | 12.43% | 0.450 |
Earnings due: May 15
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bullish Engulfing | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 12.43% | |
| Below Lower BB | Weakness | 12.43% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | 2 days ago |
| Up 5% | 2 days ago |
| Up 3% | 2 days ago |
| Up 2% | 2 days ago |
| Up 1% | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 2024-05-15
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Diabetes Organ Systems Infection Hypertension Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.35 |
| 52 Week Low | 0.33 |
| Average Volume | 19,113 |
| 200-Day Moving Average | 2.529 |
| 50-Day Moving Average | 4.919 |
| 20-Day Moving Average | 4.479 |
| 10-Day Moving Average | 4.103 |
| Average True Range | 0.391 |
| RSI (14) | 42.53 |
| ADX | 21.11 |
| +DI | 22.075 |
| -DI | 34.825 |
| Chandelier Exit (Long, 3 ATRs) | 4.146 |
| Chandelier Exit (Short, 3 ATRs) | 4.594 |
| Upper Bollinger Bands | 5.365 |
| Lower Bollinger Band | 3.594 |
| Percent B (%b) | 0.27 |
| BandWidth | 39.546 |
| MACD Line | -0.335 |
| MACD Signal Line | -0.259 |
| MACD Histogram | -0.0763 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.090 | ||||
| Resistance 3 (R3) | 4.987 | 4.543 | 4.920 | ||
| Resistance 2 (R2) | 4.543 | 4.284 | 4.595 | 4.863 | |
| Resistance 1 (R1) | 4.307 | 4.123 | 4.425 | 4.410 | 4.807 |
| Pivot Point | 3.863 | 3.863 | 3.923 | 3.915 | 3.863 |
| Support 1 (S1) | 3.627 | 3.604 | 3.745 | 3.730 | 3.333 |
| Support 2 (S2) | 3.183 | 3.443 | 3.235 | 3.277 | |
| Support 3 (S3) | 2.947 | 3.183 | 3.220 | ||
| Support 4 (S4) | 3.050 |
